Literature DB >> 1440853

Acute vascular rejection in renal transplantation--diagnosis and outcome.

K T Salmela1, E O von Willebrand, L E Kyllönen, B H Eklund, K A Höckerstedt, H M Isoniemi, L Krogerus, E Taskinen, P J Ahonen.   

Abstract

Thirty episodes of histologically verified acute vascular rejection in kidney transplant recipients were studied. In 11 grafts the rejection was mainly vascular, whereas in 19 grafts a concomitant cellular rejection was seen. Histological features prognostic for bad outcome were glomerular necrosis and thrombi in the arteries and arterioles. Characteristic findings in transplant cytology, i.e., high number of monocytes and low number of lymphocytes and blast cells were noted prior to the onset of clinical signs of rejection, and this finding was also persisting throughout the rejection episode. The numbers of lymphocytes and blast cells were significantly lower in grafts with a pure vascular rejection than in grafts with a concomitant cellular rejection. Vascular rejection was reversible in 15 cases. As rescue therapy plasmapheresis and added immunosuppression were often successful.

Entities:  

Mesh:

Year:  1992        PMID: 1440853     DOI: 10.1097/00007890-199211000-00017

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Evaluation of oxidative stress markers for the early diagnosis of allograft rejection in feline renal allotransplant recipients with normal renal function.

Authors:  Krista B Halling; Gary W Ellison; Don Armstrong; Kasumi Aoyagi; Carol J Detrisac; John P Graham; Susan P Newell; Frank G Martin; James M Van Gilder
Journal:  Can Vet J       Date:  2004-10       Impact factor: 1.008

2.  B-cell complement dependent cytotoxic crossmatch positivity is an independent risk factor for long-term renal allograft survival.

Authors:  Hyeon Seok Hwang; Hye Eun Yoon; Bum Soon Choi; Eun Jee Oh; Ji Il Kim; In Sung Moon; Yong Soo Kim; Chul Woo Yang
Journal:  J Korean Med Sci       Date:  2011-03-28       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.